Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Sex Differences in Urothelial Bladder Cancer Survival.

Radkiewicz C, Edgren G, Johansson ALV, Jahnson S, Häggström C, Akre O, Lambe M, Dickman PW.

Clin Genitourin Cancer. 2019 Nov 6. pii: S1558-7673(19)30324-6. doi: 10.1016/j.clgc.2019.10.020. [Epub ahead of print]

PMID:
31787542
2.

Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).

Menon U, Vedsted P, Zalounina Falborg A, Jensen H, Harrison S, Reguilon I, Barisic A, Bergin RJ, Brewster DH, Butler J, Brustugun OT, Bucher O, Cairnduff V, Gavin A, Grunfeld E, Harland E, Kalsi J, Knudsen AK, Lambe M, Law RJ, Lin Y, Malmberg M, Turner D, Neal RD, White V, Weller D.

BMJ Open. 2019 Nov 27;9(11):e025895. doi: 10.1136/bmjopen-2018-025895.

3.

Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.

Tendler S, Holmqvist M, Wagenius G, Lewensohn R, Lambe M, De Petris L.

Lung Cancer. 2020 Jan;139:111-117. doi: 10.1016/j.lungcan.2019.11.008. Epub 2019 Nov 14.

PMID:
31760352
4.

Data must be shared-also with researchers outside of Europe.

Ursin G, Stenbeck M, Chang-Claude J, Gunter M, Kaaks R, Kampman E, Lambe M, van Leeuwen F, Magnusson P, Malila N, Nilbert MC, Romundstad PR, Röösli M, Ryel AL, Dos-Santos-Silva I, Storm HH, Swerdlow A, Vineis P, Knudsen GPS.

Lancet. 2019 Nov 23;394(10212):1902-1903. doi: 10.1016/S0140-6736(19)32633-9. Epub 2019 Nov 7. No abstract available.

PMID:
31708191
5.

Sharing data safely while preserving privacy.

Ursin G, Malila N, Chang-Claude J, Gunter M, Kaaks R, Kampman E, Lambe M, van Leeuwen F, Magnusson P, Nilbert MC, Romundstad PR, Röösli M, Ryel AL, Dos-Santos-Silva I, Stenbeck M, Storm HH, Swerdlow A, Vineis P, Knudsen GPS.

Lancet. 2019 Nov 23;394(10212):1902. doi: 10.1016/S0140-6736(19)32603-0. Epub 2019 Nov 7. No abstract available.

PMID:
31708190
6.

Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study.

Löfling L, Karimi A, Sandin F, Bahmanyar S, Kieler H, Lambe M, Lamberg K, Wagenius G.

Acta Oncol. 2019 Nov;58(11):1618-1627. doi: 10.1080/0284186X.2019.1638521. Epub 2019 Aug 2.

PMID:
31373239
7.

Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis.

Santaolalla A, Garmo H, Grigoriadis A, Ghuman S, Hammar N, Jungner I, Walldius G, Lambe M, Holmberg L, Van Hemelrijck M.

BMC Mol Cell Biol. 2019 Jul 23;20(1):28. doi: 10.1186/s12860-019-0210-7.

8.

Sex and survival in non-small cell lung cancer: A nationwide cohort study.

Radkiewicz C, Dickman PW, Johansson ALV, Wagenius G, Edgren G, Lambe M.

PLoS One. 2019 Jun 27;14(6):e0219206. doi: 10.1371/journal.pone.0219206. eCollection 2019.

9.

Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.

Willén L, Berglund A, Bergström S, Bergqvist M, Öjdahl-Bodén A, Wagenius G, Lambe M.

Lung Cancer. 2019 May;131:40-46. doi: 10.1016/j.lungcan.2019.03.004. Epub 2019 Mar 7.

PMID:
31027696
10.

Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenarios.

Bower H, Andersson TM, Syriopoulou E, Rutherford MJ, Lambe M, Ahlgren J, Dickman PW, Lambert PC.

Breast. 2019 Jun;45:75-81. doi: 10.1016/j.breast.2019.03.005. Epub 2019 Mar 12.

PMID:
30904700
11.

Estimated Glomerular Filtration Rate and the Risk of Cancer.

Xu H, Matsushita K, Su G, Trevisan M, Ärnlöv J, Barany P, Lindholm B, Elinder CG, Lambe M, Carrero JJ.

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):530-539. doi: 10.2215/CJN.10820918. Epub 2019 Mar 14.

PMID:
30872279
12.

Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age.

Plym A, Johansson ALV, Bower H, Voss M, Holmberg L, Fredriksson I, Lambe M.

Breast. 2019 Jun;45:48-55. doi: 10.1016/j.breast.2019.02.012. Epub 2019 Mar 2.

PMID:
30852409
13.

Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions.

Eden M, Harrison S, Griffin M, Lambe M, Pettersson D, Gavin A, Brewster DH, Lin Y, Johannesen TB, Milne RL, Farrugia H, Nishri D, King MJ, Huws DW, Warlow J, Turner D, Earle CC, Peake M, Rashbass J.

Cancer Epidemiol. 2019 Feb;58:184-192. doi: 10.1016/j.canep.2018.10.019. Epub 2019 Jan 9.

PMID:
30639877
14.

Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.

Johansson ALV, Weibull CE, Fredriksson I, Lambe M.

Breast Cancer Res Treat. 2019 Apr;174(2):489-503. doi: 10.1007/s10549-018-05083-x. Epub 2018 Dec 14.

15.

Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP).

Weller D, Menon U, Zalounina Falborg A, Jensen H, Barisic A, Knudsen AK, Bergin RJ, Brewster DH, Cairnduff V, Gavin AT, Grunfeld E, Harland E, Lambe M, Law RJ, Lin Y, Malmberg M, Turner D, Neal RD, White V, Harrison S, Reguilon I; ICBP Module 4 Working Group, Vedsted P.

BMJ Open. 2018 Nov 27;8(11):e023870. doi: 10.1136/bmjopen-2018-023870.

16.

No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.

Frisk G, Ekberg S, Lidbrink E, Eloranta S, Sund M, Fredriksson I, Lambe M, Smedby KE.

Breast Cancer Res. 2018 Nov 20;20(1):142. doi: 10.1186/s13058-018-1065-0.

17.

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.

Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M.

Cancer Causes Control. 2019 Feb;30(2):195-206. doi: 10.1007/s10552-018-1093-1. Epub 2018 Nov 12.

PMID:
30421156
18.

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, Van Hemelrijck M, Lambe M.

Breast Cancer Res Treat. 2018 Nov;172(1):167-177. doi: 10.1007/s10549-018-4890-z. Epub 2018 Jul 21.

19.

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ejerblad E.

Br J Haematol. 2018 Jun;181(5):614-627. doi: 10.1111/bjh.15243. Epub 2018 Apr 29.

PMID:
29707769
20.

Public online reporting from a nationwide population-based clinical prostate cancer register.

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

BJU Int. 2018 Jul;122(1):8-10. doi: 10.1111/bju.14213. Epub 2018 Apr 17. No abstract available.

21.

Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study.

Joneborg U, Folkvaljon Y, Papadogiannakis N, Lambe M, Marions L.

Acta Oncol. 2018 Aug;57(8):1094-1099. doi: 10.1080/0284186X.2018.1438653. Epub 2018 Feb 16.

PMID:
29451409
22.

Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.

Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Van Hemelrijck M.

Oncotarget. 2017 Dec 4;9(1):774-782. doi: 10.18632/oncotarget.22891. eCollection 2018 Jan 2.

23.

Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.

Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P.

Scand J Urol. 2018 Apr;52(2):143-150. doi: 10.1080/21681805.2018.1426039. Epub 2018 Feb 1.

PMID:
29385878
24.

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.

Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P.

Int J Cancer. 2018 Jun 15;142(12):2478-2484. doi: 10.1002/ijc.31272. Epub 2018 Feb 2.

25.

Loss in working years after a breast cancer diagnosis.

Plym A, Bower H, Fredriksson I, Holmberg L, Lambert PC, Lambe M.

Br J Cancer. 2018 Mar 6;118(5):738-743. doi: 10.1038/bjc.2017.456. Epub 2018 Jan 23.

26.

Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.

Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

Int J Cancer. 2018 Jun 1;142(11):2254-2262. doi: 10.1002/ijc.31256. Epub 2018 Jan 26.

27.

Nordic Cancer Registries - an overview of their procedures and data comparability.

Pukkala E, Engholm G, Højsgaard Schmidt LK, Storm H, Khan S, Lambe M, Pettersson D, Ólafsdóttir E, Tryggvadóttir L, Hakanen T, Malila N, Virtanen A, Johannesen TB, Larønningen S, Ursin G.

Acta Oncol. 2018 Apr;57(4):440-455. doi: 10.1080/0284186X.2017.1407039. Epub 2017 Dec 11.

PMID:
29226751
28.

Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.

Johansson ALV, Andersson TM, Hsieh CC, Jirström K, Cnattingius S, Fredriksson I, Dickman PW, Lambe M.

Int J Cancer. 2018 Apr 1;142(7):1343-1354. doi: 10.1002/ijc.31174. Epub 2017 Dec 4.

29.

Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status.

Bower H, Andersson TM, Crowther MJ, Dickman PW, Lambe M, Lambert PC.

Am J Epidemiol. 2018 Apr 1;187(4):828-836. doi: 10.1093/aje/kwx303.

PMID:
29020167
30.

Serum biomarkers to predict risk of testicular and penile cancer in AMORIS.

Ghoshal A, Garmo H, Arthur R, Hammar N, Jungner I, Malmström H, Lambe M, Walldius G, Hemelrijck MV.

Ecancermedicalscience. 2017 Aug 23;11:762. doi: 10.3332/ecancer.2017.762. eCollection 2017.

31.

Sex differences in cancer risk and survival: A Swedish cohort study.

Radkiewicz C, Johansson ALV, Dickman PW, Lambe M, Edgren G.

Eur J Cancer. 2017 Oct;84:130-140. doi: 10.1016/j.ejca.2017.07.013. Epub 2017 Aug 10.

PMID:
28802709
32.

The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study.

Nilsson J, Berglund A, Bergström S, Bergqvist M, Lambe M.

Acta Oncol. 2017 Jul;56(7):949-956. doi: 10.1080/0284186X.2017.1324213. Epub 2017 May 9.

PMID:
28486004
33.

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.

Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. No abstract available.

34.

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

J Clin Oncol. 2017 May 1;35(13):1430-1436. doi: 10.1200/JCO.2016.69.5304. Epub 2017 Mar 13.

35.

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study.

Yiu A, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Oncotarget. 2017 Jun 27;8(26):42332-42342. doi: 10.18632/oncotarget.16198.

36.

Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.

Melvin JC, Garmo H, Holmberg L, Hammar N, Walldius G, Jungner I, Lambe M, Van Hemelrijck M.

BMC Cancer. 2017 Apr 4;17(1):246. doi: 10.1186/s12885-017-3232-6.

37.

Serum inflammatory markers and colorectal cancer risk and survival.

Ghuman S, Van Hemelrijck M, Garmo H, Holmberg L, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Br J Cancer. 2017 May 9;116(10):1358-1365. doi: 10.1038/bjc.2017.96. Epub 2017 Apr 4.

38.

Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.

Shackshaft L, Van Hemelrijck M, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Wulaningsih W.

Breast Cancer Res. 2017 Mar 6;19(1):22. doi: 10.1186/s13058-017-0816-7.

39.

Cohort Profile: The AMORIS cohort.

Walldius G, Malmström H, Jungner I, de Faire U, Lambe M, Van Hemelrijck M, Hammar N.

Int J Epidemiol. 2017 Aug 1;46(4):1103-1103i. doi: 10.1093/ije/dyw333. No abstract available.

PMID:
28158674
40.

The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.

Larfors G, Sandin F, Richter J, Själander A, Stenke L, Lambe M, Höglund M.

Eur J Haematol. 2017 Apr;98(4):398-406. doi: 10.1111/ejh.12845. Epub 2017 Jan 16.

PMID:
28009456
41.

Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.

Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K.

Breast Cancer Res. 2016 Dec 1;18(1):119.

42.

Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor.

Hookham MB, Ali IH, O'Neill CL, Hackett E, Lambe MH, Schmidt T, Medina RJ, Chamney S, Rao B, McLoone E, Sweet D, Stitt AW, Brazil DP.

Stem Cell Res Ther. 2016 Nov 29;7(1):173.

43.

Profiling cancer testis antigens in non-small-cell lung cancer.

Djureinovic D, Hallström BM, Horie M, Mattsson JSM, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler JG, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P.

JCI Insight. 2016 Jul 7;1(10):e86837. doi: 10.1172/jci.insight.86837.

44.

Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies.

Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, Malmström H, Lambe M, Hammar N, Walldius G, Jungner I, Van Hemelrijck M.

Int J Mol Sci. 2016 Sep 6;17(9). pii: E1487. doi: 10.3390/ijms17091487.

45.

A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years.

Wadsten C, Heyman H, Holmqvist M, Ahlgren J, Lambe M, Sund M, Wärnberg F.

Acta Oncol. 2016 Nov;55(11):1338-1343. Epub 2016 Aug 22.

PMID:
27548561
46.

Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.

Wulaningsih W, Holmberg L, Garmo H, Karagiannis SN, Ahlstedt S, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, Van Hemelrijck M.

Oncoimmunology. 2016 Mar 28;5(6):e1154250. doi: 10.1080/2162402X.2016.1154250. eCollection 2016 Jun.

47.

An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation.

Weller D, Vedsted P, Anandan C, Zalounina A, Fourkala EO, Desai R, Liston W, Jensen H, Barisic A, Gavin A, Grunfeld E, Lambe M, Law RJ, Malmberg M, Neal RD, Kalsi J, Turner D, White V, Bomb M, Menon U; ICBP Module 4 Working Group*.

BMJ Open. 2016 Jul 25;6(7):e009641. doi: 10.1136/bmjopen-2015-009641.

48.

Socioeconomic factors and penile cancer risk and mortality; a population-based study.

Torbrand C, Wigertz A, Drevin L, Folkvaljon Y, Lambe M, Håkansson U, Kirrander P.

BJU Int. 2017 Feb;119(2):254-260. doi: 10.1111/bju.13534. Epub 2016 Jul 4.

49.

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group.

Ann Intern Med. 2016 Aug 2;165(3):161-6. doi: 10.7326/M15-2306. Epub 2016 Jun 14.

PMID:
27295519
50.

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A.

Leukemia. 2016 Jul;30(7):1562-7. doi: 10.1038/leu.2016.59. Epub 2016 Mar 8.

PMID:
27080811

Supplemental Content

Support Center